Literature DB >> 2702889

5-Aminosalicylic acid concentration in mucosal interstitium of cat small and large intestine.

M B Grisham1, D N Granger.   

Abstract

Uncertainty regarding the concentration of 5-ASA within the mucosal interstitium has been a major limitation of defining the protective mechanisms of 5-ASA in intestinal inflammation. Therefore, we measured the concentration of 5-ASA in intestinal lymph and venous plasma during luminal perfusion of the cat small and large intestine with 10 mM 5-ASA. Blood and lymph flows were measured in each segment. 5-ASA and N-acetyl-5-ASA were extracted from plasma and lymph and quantified using fluorescence spectroscopy. Luminal perfusion of the terminal ileum with 5-ASA resulted in the following concentration profile: intestinal venous plasma (143 +/- 30 micrograms/ml) much greater than lymph (43 +/- 17 micrograms/ml) = systemic arterial plasma (40 +/- 11 micrograms/ml). In the colon the local venous plasma concentration of 5-ASA was 20 +/- 6 micrograms/ml compared to 2.0 +/- 1.0 micrograms/ml in systemic arterial plasma. N-Acetyl-5-ASA was found to comprise less than 5% of the total metabolite concentration in both ileum and colon. We also found that 58% of luminal 5-ASA was absorbed per minute in the terminal ileum, whereas only 3%/min was absorbed from the colon. The results of this study suggest that: (1) the mucosal interstitial concentration of 5-ASA in the terminal ileum and colon are approximately 100 micrograms/ml (654 microM) and 20 micrograms/ml (164 microM), respectively; and (2) the rate of 5-ASA absorption in the terminal ileum is approximately seven times greater than that in the colon.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2702889     DOI: 10.1007/BF01536335

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  19 in total

1.  Inhibition of soybean lipoxygenase by sulfasalazine and 5-aminosalicylic acid: a possible mode of action in ulcerative colitis.

Authors:  J C Sircar; C F Schwender; M E Carethers
Journal:  Biochem Pharmacol       Date:  1983-01-01       Impact factor: 5.858

Review 2.  Intestinal blood flow.

Authors:  D N Granger; P D Richardson; P R Kvietys; N A Mortillaro
Journal:  Gastroenterology       Date:  1980-04       Impact factor: 22.682

3.  Therapeutic efficacy of sulfasalazine and its metabolites in patients with ulcerative colitis and Crohn's disease.

Authors:  U Klotz; K Maier; C Fischer; K Heinkel
Journal:  N Engl J Med       Date:  1980-12-25       Impact factor: 91.245

4.  Sulfasalazine inhibits the synthesis of chemotactic lipids by neutrophils.

Authors:  W F Stenson; E Lobos
Journal:  J Clin Invest       Date:  1982-02       Impact factor: 14.808

5.  Topical administration of 5-aminosalicylic acid enemas in patients with ulcerative colitis. Studies on rectal absorption and excretion.

Authors:  M Campieri; G A Lanfranchi; S Boschi; C Brignola; G Bazzocchi; P Gionchetti; M R Minguzzi; A Belluzzi; G Labò
Journal:  Gut       Date:  1985-04       Impact factor: 23.059

6.  5-aminosalicylic acid in a slow-release preparation: bioavailability, plasma level, and excretion in humans.

Authors:  S N Rasmussen; S Bondesen; E F Hvidberg; S H Hansen; V Binder; S Halskov; H Flachs
Journal:  Gastroenterology       Date:  1982-11       Impact factor: 22.682

7.  Kinetics of 5-aminosalicylic acid after jejunal instillation in man.

Authors:  O Haagen Nielsen; S Bondesen
Journal:  Br J Clin Pharmacol       Date:  1983-12       Impact factor: 4.335

8.  Distribution and metabolism in healthy volunteers of disodium azodisalicylate, a potential therapeutic agent for ulcerative colitis.

Authors:  C P Willoughby; J K Aronson; H Agback; N O Bodin; S C Truelove
Journal:  Gut       Date:  1982-12       Impact factor: 23.059

9.  Effect of anti-inflammatory drugs on xanthine oxidase and xanthine oxidase induced depolymerization of hyaluronic acid.

Authors:  G Carlin; R Djursäter; G Smedegård; B Gerdin
Journal:  Agents Actions       Date:  1985-07

10.  Effect of sulphapyridine, 5-aminosalicylic acid, and placebo in patients with idiopathic proctitis: a study to determine the active therapeutic moiety of sulphasalazine.

Authors:  P A van Hees; J H Bakker; J H van Tongeren
Journal:  Gut       Date:  1980-07       Impact factor: 23.059

View more
  6 in total

Review 1.  Sulfasalazine. Multiplicity of action.

Authors:  T S Gaginella; R E Walsh
Journal:  Dig Dis Sci       Date:  1992-06       Impact factor: 3.199

2.  5-aminosalicylic acid prevents oxidant mediated damage of glyceraldehyde-3-phosphate dehydrogenase in colon epithelial cells.

Authors:  S M McKenzie; W F Doe; G D Buffinton
Journal:  Gut       Date:  1999-02       Impact factor: 23.059

3.  Superoxide inhibition following different stimuli of respiratory burst and metabolism of aminosalicylates in neutrophils.

Authors:  H Allgayer; S Rang; U Klotz; P Böhne; J Retey; W Kruis; R Gugler
Journal:  Dig Dis Sci       Date:  1994-01       Impact factor: 3.199

4.  Prooxidant properties of 5-aminosalicylic acid. Possible mechanism for its adverse side effects.

Authors:  M B Grisham; K Ware; S Marshall; T Yamada; I S Sandhu
Journal:  Dig Dis Sci       Date:  1992-09       Impact factor: 3.199

5.  Modulation of cellular phospholipid fatty acids and leukotriene B4 synthesis in the human intestinal cell (CaCo-2).

Authors:  V C Dias; J L Wallace; H G Parsons
Journal:  Gut       Date:  1992-05       Impact factor: 23.059

6.  The Protective Effect of 5-Aminosalicylic Acid Against Non-Steroidal Anti-Inflammatory Drug-Induced Injury Through Free Radical Scavenging in Small Intestinal Epithelial Cells.

Authors:  Eun Suk Jung; Hyun Joo Jang; Eun Mi Hong; Hye Li Lim; Sang Pyo Lee; Sea Hyub Kae; Jin Lee
Journal:  Medicina (Kaunas)       Date:  2020-10-01       Impact factor: 2.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.